A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses.
Cancers
Koopman, Bart B; Cajiao Garcia, Betzabel N BN; Kuijpers, Chantal C H J CCHJ; Damhuis, Ronald A M RAM; van der Wekken, Anthonie J AJ; Groen, Harry J M HJM; Schuuring, Ed E; Willems, Stefan M SM; van Kempen, Léon C LC
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment.
British Journal Of Cancer
Kuiper, J L JL; Hashemi, S M S SM; Thunnissen, E E; Snijders, P J F PJ; Grünberg, K K; Bloemena, E E; Sie, D D; Postmus, P E PE; Heideman, D A M DA; Smit, E F EF
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.
Clinical Pharmacology And Therapeutics
Phelps, M A MA; Stinchcombe, T E TE; Blachly, J S JS; Zhao, W W; Schaaf, L J LJ; Starrett, S L SL; Wei, L L; Poi, M M; Wang, D D; Papp, A A; Aimiuwu, J J; Gao, Y Y; Li, J J; Otterson, G A GA; Hicks, W J WJ; Socinski, M A MA; Villalona-Calero, M A MA
Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors.
British Journal Of Cancer
Weber, F F; Fukino, K K; Sawada, T T; Williams, N N; Sweet, K K; Brena, R M RM; Plass, C C; Caldes, T T; Mutter, G L GL; Villalona-Calero, M A MA; Eng, C C